Takara Bio (FRA:TF2) ROCE %: -0.20% (As of Mar. 2026)


FRA:TF2 Takara Bio Inc FRA:TF2
71 GF Score
Price €5.95
GF Value €4.45
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Takara Bio ROCE %?

Takara Bio FRA:TF2 71 ROCE % is -0.20% as of Mar. 2026. GuruFocus rates FRA:TF2 with a GF Score™ of 71/100 and a GF Value™ of €4.45 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Takara Bio's annualized ROCE % for the quarter that ended in Mar. 2026 was -0.20%.

Takara Bio  (FRA:TF2) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Takara Bio ROCE % Related Terms

Takara Bio ROCE % Historical Data

* Premium members only.

The historical data trend for Takara Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takara Bio ROCE % Chart

Takara Bio Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.38 19.09 2.35 1.75 -6.62

Takara Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.79 -5.49 -14.17 -7.83 -0.20
FRA:TF2
71GF Score
Takara Bio Inc FRA:TF2
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takara Bio ROCE % Calculation

Takara Bio's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-46.978/( ( (777.78 - 44.253) + (728.587 - 42.442) )/ 2 )
=-46.978/( (733.527+686.145)/ 2 )
=-46.978/709.836
=-6.62 %

Takara Bio's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-1.332/( ( (714.673 - 42.784) + (728.587 - 42.442) )/ 2 )
=-1.332/( ( 671.889 + 686.145 )/ 2 )
=-1.332/679.017
=-0.20 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.20% mean?
Takara Bio (FRA:TF2) has a ROCE % of -0.20% as of Mar. 2026.
Is Takara Bio's ROCE % too high?
Takara Bio's current ROCE % is -0.20%. Overall, Takara Bio has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's ROCE % compare to VRTX and REGN?
Takara Bio's ROCE % of -0.20% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Takara Bio's current ROCE % is -0.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.45, compared to a current price of €5.95 — trading 33.7% above its estimated fair value. The current ROCE % is -0.20%. Takara Bio's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current ROCE % is -0.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takara Bio (FRA:TF2) Overvalued in 2026?

Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued. The current stock price of €5.95 is trading 33.7% above its estimated GF Value™ of €4.45. GuruFocus considers Takara Bio to be Significantly Overvalued.

Key valuation signals for FRA:TF2:

  • ROCE %: -0.20%
  • GF Value™: €4.45 vs. price of €5.95 (33.7% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takara Bio Business Description

Other Exchanges 4974:Japan
Address Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
71GF Score

Get the complete analysis for FRA:TF2

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.95
Price
€4.45
GF Value